Cell Signaling · Skim version

Ras to MAPK: The Kinase Cascade

About 1 min to skim · 3 figures

Read the full lesson → Skim the whole course →

The guiding idea

A growth factor at the cell surface switches on Ras, and a relay of three kinases carries the message to the cell's proteins and genes. The same relay, stuck on, is found in many cancers, and in PC12 cells how long it stays on seems to decide what the cell does.

How does a signal get from an active receptor at the membrane to a gene in the nucleus?

  1. The idea: Ras-GTP catches Raf and holds it at the membrane

  2. Three kinases in a row, with a two-phosphate lock at the end

    AI-generated illustration: a schematic Raf–MEK–ERK relay narrows at MEK, whose known substrates are almost exclusively ERK. Active ERK branches to many cytoplasmic targets and into the nucleus, where it phosphorylates Elk-1, which helps switch on the immediate early gene c-fos.
    A narrow relay that ends in a wide fan: MEK has almost no known substrate but ERK, while ERK reaches many cytoplasmic proteins and, in the nucleus, transcription factors such as Elk-1, which helps switch on c-fos. AI-generated illustration
  3. One design, several cascades

  4. How long is the signal on?

  5. When the cascade is stuck on

    AI-generated illustration: two panels compare the effects of the same always-on MEK1. A PC12 cell grows neurites without NGF on the left. NIH 3T3 mouse fibroblasts form a piled-up focus on the right.
    The same permanently active MEK1 tells a PC12 cell to grow neurites without NGF and tells mouse fibroblasts to pile up into foci. AI-generated illustration
    AI-generated illustration: two panels and one inset. Left, a schematic B-Raf V600E target with its pairing state omitted and partner requirement marked as debated; vemurafenib occupies its ATP pocket and blocks downstream MEK–ERK signalling. Right, active Ras is lipid-anchored on the cytoplasmic face of the membrane beside paired Raf proteins. Drug-bound Raf activates its drug-free partner, which signals to MEK and ERK. The inset shows trametinib occupying a separate MEK pocket beside the ATP site.
    Vemurafenib occupies the ATP pocket of B-Raf V600E and inhibits signalling to MEK and ERK. The mutant needs no Ras-GTP, but whether it acts without a partner is debated; its pairing state is omitted here. With normal B-Raf and active Ras, a drug-bound Raf can activate a drug-free Raf partner, increasing MEK–ERK signalling. Trametinib binds a pocket beside the MEK ATP site and holds MEK inactive, blocking the cascade below Raf. AI-generated illustration
  6. Going deeper

Read the full lesson → Skim the whole course →